EGFR and non-small cell lung carcinoma: In this phase 3 trial (NCT04538664), patients with advanced NSCLC and EGFR exon 20 insertions who had not undergone previous systemic treatment were randomly assigned in a 1:1 ratio to receive either intravenous amivantamab plus chemotherapy (amivantamab–chemotherapy) or chemotherapy alone (164).